| 1. |
- Fauria, K., et al.
(författare)
-
Exploring cognitive and biological correlates of sleep quality and their potential links with Alzheimer's disease (ALFASleep project): protocol for an observational study
- 2022
-
Ingår i: Bmj Open. - : BMJ. - 2044-6055. ; 12:12
-
Tidskriftsartikel (refereegranskat)abstract
- INTRODUCTION: The growing worldwide prevalence of Alzheimer's disease (AD) and the lack of effective treatments pose a dire medical challenge. Sleep disruption is also prevalent in the ageing population and is increasingly recognised as a risk factor and an early sign of AD. The ALFASleep project aims to characterise sleep with subjective and objective measurements in cognitively unimpaired middle/late middle-aged adults at increased risk of AD who are phenotyped with fluid and neuroimaging AD biomarkers. This will contribute to a better understanding of the pathophysiological mechanisms linking sleep with AD, thereby paving the way for the development of non-invasive biomarkers and preventive strategies targeting sleep. METHODS AND ANALYSIS: We will invite 200 participants enrolled in the ALFA+ (for ALzheimer and FAmilies) prospective observational study to join the ALFASleep study. ALFA+ participants are cognitively unimpaired middle-aged/late middle-aged adults who are followed up every 3years with a comprehensive set of evaluations including neuropsychological tests, blood and cerebrospinal fluid (CSF) sampling, and MRI and positron emission tomography acquisition. ALFASleep participants will be additionally characterised with actigraphy and CSF-orexin-A measurements, and a subset (n=90) will undergo overnight polysomnography. We will test associations of sleep measurements and CSF-orexin-A with fluid biomarkers of AD and glial activation, neuroimaging outcomes and cognitive performance. In case we found any associations, we will test whether changes in AD and/or glial activation markers mediate the association between sleep and neuroimaging or cognitive outcomes and whether sleep mediates associations between CSF-orexin-A and AD biomarkers. ETHICS AND DISSEMINATION: The ALFASleep study protocol has been approved by the independent Ethics Committee Parc de Salut Mar, Barcelona (2018/8207/I). All participants have signed a written informed consent before their inclusion (approved by the same ethics committee). Study findings will be presented at national and international conferences and submitted for publication in peer-reviewed journals. TRIAL REGISTRATION NUMBER: NCT04932473.
|
|
| 2. |
- Stankeviciute, L., et al.
(författare)
-
Differential effects of sleep on brain structure and metabolism at the preclinical stages of AD
- 2023
-
Ingår i: Alzheimers & Dementia. - 1552-5260. ; 19:12, s. 5371-5386
-
Tidskriftsartikel (refereegranskat)abstract
- INTRODUCTIONPoor sleep quality is associated with cognitive outcomes in Alzheimer's disease (AD). We analyzed the associations between self-reported sleep quality and brain structure and function in cognitively unimpaired (CU) individuals. METHODSCU adults (N = 339) underwent structural magnetic resonance imaging, lumbar puncture, and the Pittsburgh Sleep Quality Index (PSQI) questionnaire. A subset (N = 295) performed [18F] fluorodeoxyglucose positron emission tomography scans. Voxel-wise associations with gray matter volumes (GMv) and cerebral glucose metabolism (CMRGlu) were performed including interactions with cerebrospinal fluid (CSF) AD biomarkers status. RESULTSPoorer sleep quality was associated with lower GMv and CMRGlu in the orbitofrontal and cingulate cortices independently of AD pathology. Self-reported sleep quality interacted with altered core AD CSF biomarkers in brain areas known to be affected in preclinical AD stages. DISCUSSIONPoor sleep quality may impact brain structure and function independently from AD pathology. Alternatively, AD-related neurodegeneration in areas involved in sleep-wake regulation may induce or worsen sleep disturbances.Poor sleep impacts brain structure and function independent of Alzheimer's disease (AD) pathology.Poor sleep exacerbates brain changes observed in preclinical AD.Sleep is an appealing therapeutic strategy for preventing AD. Highlights
|
|
| 3. |
- Garskaite, Edita, et al.
(författare)
-
The Accessibility of the Cell Wall in Scots Pine (Pinus sylvestris L.) Sapwood to Colloidal Fe3O4 Nanoparticles
- 2021
-
Ingår i: ACS Omega. - : American Chemical Society (ACS). - 2470-1343. ; 6:33, s. 21719-21729
-
Tidskriftsartikel (refereegranskat)abstract
- This work presents a rapid and facile way to access the cell wall of wood with magnetic nanoparticles (NPs), providing insights into a method of wood modification to prepare hybrid bio-based functional materials. Diffusion-driven infiltration into Scots pine (Pinus sylvestris L.) sapwood was achieved using colloidal Fe3O4 nanoparticles. Optical microscopy, scanning electron microscopy/energy-dispersive X-ray spectroscopy, transmission electron microscopy, and X-ray powder diffraction analyses were used to detect and assess the accessibility of the cell wall to Fe3O4. The structural changes, filling of tracheids (cell lumina), and NP infiltration depth were further evaluated by performing X-ray microcomputed tomography analysis. Fourier transform infrared spectroscopy was used to assess the chemical changes in Scots pine induced by the interaction of the wood with the solvent. The thermal stability of Fe3O4-modified wood was studied by thermogravimetric analysis. Successful infiltration of the Fe3O4 NPs was confirmed by measuring the magnetic properties of cross-sectioned layers of the modified wood. The results indicate the feasibility of creating multiple functionalities that may lead to many future applications, including structural nanomaterials with desirable thermal properties, magnetic devices, and sensors.
|
|
